We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Method Allows Safer Dosing of Anticoagulants

By HospiMedica International staff writers
Posted on 19 Dec 2011
A new method for measuring prothrombin time (PTT) improves the accuracy of anticoagulant risk assessments, reliably identifying atrial fibrillation (AF) patients at risk of serious complications.

Researchers at the Sahlgrenska Academy at the University of Gothenburg (Sweden) and Chalmers University of Technology (Göteborg, Sweden) conducted a study involving 19,180 patients with AF receiving warfarin therapy to evaluate the association of time in therapeutic range (TTR) of International Normalized Ratio (INR) and standard deviation of transformed (SDT) INR (SDT(INR)), to determine which is the more prognostically important measurement for all-cause mortality, stroke, bleeding, and hospitalization. More...


The results showed that SDT(INR) was a more accurate prognostic than TTR. One standard deviation (SD) higher of SDT(INR) had a hazard ratio of 1.59 of mortality, compared with 1.18 for one SD lower of TTR. For stroke, bleeding, and hospitalization, the HR was also higher for the SDT(INR) than for the TTR. When both metrics were included in the same analysis, only the SDT(INR) was of significant predictive value. The study was published ahead of print on August 17, 2011, in Thrombosis Research.

“Our method takes account of how blood viscosity goes up and down. This meant that we could establish far more reliably which patients were at risk of a stroke, hemorrhaging or dying,” said lead author Marcus Lind, PhD, a postdoctoral researcher at the Sahlgrenska Academy. “This is also important given the current debate about switching some patients who don't settle on warfarin to a different kind of medication. The new method pinpoints these patients more accurately.”

Warfarin, which acts by inhibiting the production of vitamin K–dependent clotting factors, thereby prolonging the PTT, is used in patients with persistent AF who are at higher risk for thromboembolic complications because of advanced age, history of coronary artery disease or stroke, or presence of left-sided heart failure; warfarin therapy is monitored using INR, which is derived from PTT. The treatment modality is challenging due to the narrow therapeutic window for efficacy and the risk of major bleeding, such as intracranial hemorrhage. To ensure efficacy and minimize harm, the INR should be kept between 2.0 and 3.0.

Related Links:
Sahlgrenska Academy
Chalmers University of Technology



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.